Persistent progress.
Cell
; 184(21): 5293-5296, 2021 10 14.
Article
en En
| MEDLINE
| ID: mdl-34562365
The highly effective and safe mRNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines draw on decades of painstaking research to overcome the many hurdles for delivering, expressing, and avoiding toxicity of therapeutic mRNA. Cell editor Nicole Neuman talked with Dr. Katalin Karikó and Dr. Drew Weissman, recipients of the 2021 Laskerâ¼DeBakey Clinical Medical Research Award, to learn more about their quest to develop mRNA-based therapeutics, which led them to the crucial discovery that modification of mRNA could prevent toxicity and increase expression. This conversation has been adapted for print below, with editing for clarity, accuracy, and length.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Biotecnología
/
ARN Mensajero
/
Vacunas Sintéticas
/
Vacunas contra la COVID-19
/
SARS-CoV-2
/
COVID-19
Tipo de estudio:
Qualitative_research
Límite:
Humans
Idioma:
En
Revista:
Cell
Año:
2021
Tipo del documento:
Article